Gain Therapeutics to Participate at the Jefferies Healthcare Conference

Rhea-AI Summary

Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. COO Matthias Alder will host a corporate presentation on June 10 at 8:00 AM ET, with a live webcast available on the company's website. Gain Therapeutics focuses on transforming drug discovery through its proprietary technology, SEE-Tx®, which identifies novel allosteric binding sites for various diseases. Their pipeline targets neurodegenerative diseases, lysosomal storage disorders, and oncology, with significant funding support for their Parkinson’s disease program.

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place June 8-10 in New York, NY. Please see additional details below:

Jefferies Healthcare Conference
Date: June 10, 2022
Time: 8:00AM ET
Format: Corporate Presentation
Webcast: Registration link

A live webcast of the presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.

Investor & Media Contact:

Noor Pahlavi
Argot Partners
(212) 600-1902
Gain@argotpartners.com

FAQ

When will Gain Therapeutics present at the Jefferies Healthcare Conference?

Gain Therapeutics will present on June 10, 2022, at the Jefferies Healthcare Conference.

Who is presenting on behalf of Gain Therapeutics at the conference?

Matthias Alder, the Chief Operating Officer, will present on behalf of Gain Therapeutics.

What time is Gain Therapeutics' presentation at the Jefferies Healthcare Conference?

The presentation is scheduled for 8:00 AM ET on June 10, 2022.

How can I access the live webcast of Gain Therapeutics' presentation?

The live webcast can be accessed through the Events section of Gain Therapeutics' website.

What is the focus of Gain Therapeutics' drug discovery platform?

Gain Therapeutics focuses on identifying novel allosteric binding sites to develop small molecule treatments for various diseases.

What diseases does Gain Therapeutics target?

Gain Therapeutics targets neurodegenerative diseases, lysosomal storage disorders, metabolic diseases, and oncology.

What support has Gain Therapeutics received for its Parkinson's disease program?

Gain Therapeutics has received funding support from The Michael J. Fox Foundation and the Eurostars-2 joint program.